Totals
- Total revenue
- $608,940
- Total expenses
- $201,203
- Contributions and grants received
- $602,092
- Grants paid
- $163,258
- Program service revenue
- $0
- Investment income
- $15,732
- Other revenue
- -$8,884
- Total assets, end of year
- $739,788
- Total liabilities, end of year
- $0
- Net assets or fund balances, end of year
- $739,788
- Program services expenses (Part IX)
- $163,258
- Management and general expenses
- $35,764
- Fundraising expenses
- $2,181
- Program service expenses (Part III)
- $163,258
Program services were 81.1% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
Line items
Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.
Revenue
Part VIII, the statement of revenue.
-
1c · Fundraising events
$29,013
-
1f · All other contributions, gifts and grants
$573,079
-
3 · Investment income
total $15,732 · excluded $15,732
-
8a · Fundraising events: gross income
$0
-
8a · Fundraising events: contributions included on line 1c
$29,013
-
8b · Fundraising events: direct expenses
$8,884
-
8c · Net income from fundraising events
total -$8,884 · excluded -$8,884
Functional expenses
Part IX, the statement of functional expenses.
-
1 · Grants to domestic organizations and governments
total $163,258 · program services $163,258
-
11b · Fees: legal
total $10,745 · management and general $10,745
-
11c · Fees: accounting
total $2,500 · management and general $2,500
-
11g · Fees: other
total $432 · management and general $432
-
12 · Advertising and promotion
total $10,090 · management and general $8,193 · fundraising $1,897
-
13 · Office expenses
total $1,131 · management and general $847 · fundraising $284
-
14 · Information technology
total $12,386 · management and general $12,386
-
23 · Insurance
total $661 · management and general $661
Balance sheet
Part X, book values.
-
1 · Cash, non-interest-bearing
beginning of year $332,051 · end of year $49,357
-
11 · Investments: publicly traded securities
end of year $690,431
-
27 · Net assets without donor restrictions
beginning of year $332,051 · end of year $739,788
Mission and programs · 2023
Mission
MED13L PROVIDES SUPPORT FOR RESEARCH, ADVANCEMENT AND RAISING AWARENESS OF THE RARE GENETIC DISEASE, MED13L. THE OBJECTIVES OF MED13L IS TO RAISE AWARENESS IN THE LOCAL, NATIONAL AND INTERNATIONAL COMMUNITY ABOUT THE RARE GENETIC DISEASE, MED13L AND TO PROVIDE FUNDING FOR RESEARCH, DEVELOPMENT AND ADVANCEMENT INTO FIGHTING THIS DISEASE. THE ULTIMATE GOAL IS TO FIND OUT MORE ABOUT WHAT CAUSES MED13L AND FIND A CURE. IN OUR ENDEAVOR TO REACH THAT GOAL, MED13L STRIVES TO CREATE A SUPPORT SYSTEM FOR FAMILIES IMPACTED BY MED13L ALL THE WHILE PROVIDING FUNDING OPPORTUNITIES TO HEALTHCARE PROFESSIONALS AND RESEARCHERS WHO ARE HELPING TO FIND A CURE TO THIS RARE GENETIC DISEASE.
Activities or mission (Part I)
THE MISSION OF THE CORPORATION IS TO: (A) INCREASE AWARENESS WITHIN LOCAL, NATIONAL AND INTERNATIONAL COMMUNITIES ABOUT MED 13L AND PROVIDE ACCURATE INFORMATION TO PATIENTS, FAMILIES, AND MEDICAL PROFESSIONALS; (B) RAISE AND PROVIDE CRUCIAL FUNDING FOR RESEARCH, DEVELOPMENT, AND ADVANCEMENTS IN UNDERSTANDING MED13L; (C) DEEPEN THE UNDERSTANDING OF THE UNDERLYING CAUSES OFMEDL3L AND DISCOVER EFFECTIVE TREATMENTS AND CURE, INCLUDING BY COLLABORATING WITH SCIENTISTS, RESEARCHERS, AND MEDICAL INSTITUTIONS TO SUPPORT STUDIES AIMED AT UNDERSTANDING MED13L BETTER, IDENTIFYING POTENTIAL TREATMENTS, AND IMPROVING THE QUALITY OF LIFE FOR AFFECTED INDIVIDUALS; ( D) DEVELOP EDUCATIONAL MATERIALS, HOST AWARENESS CAMPAIGNS, AND ORGANIZE WORKSHOPS OR CONFERENCES TO DISSEMINATE KNOWLEDGE ABOUT MED13L; (E) CREATE A SUPPORT NETWORK FOR INDIVIDUALS AND FAMILIES AFFECTED BY MEDL3L;
-
COORDINATE AND COLLABORATE WITH THE GLOBAL SCIENTIFIC COMMUNITY TO UNDERSTAND THE FUNCTION OF THE MED13L GENE IN ORDER TO DEVELOP EFFECTIVE TREATMENTS AND A CURE FOR MED13L SYNDROME. INCREASE MEDICAL COMMUNITY AND PUBLIC AWARENESS OF THE COMPLEXITY AND POTENTIAL SEVERITY OF MED13L SYNDROME. PROVIDE EDUCATIONAL AND EMOTIONAL SUPPORT FOR THOSE AFFECTED BY MED13L SYNDROME. RAISE MONEY TO FUND OUR GOALS.
Expenses $163,258 · Grants $163,258
As filed on the 2023 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part VII
-
Nick SeaverNICK SEAVER
PRESIDENT
- Total calculated
- $0
- Hours/week
- 5
-
Kelly SextonKELLY SEXTON
VICE PRESIDENT
- Total calculated
- $0
- Hours/week
- 5
-
Kathleen Barry BoychuckKATHLEEN BARRY BOYCHUCK
TREASURER
- Total calculated
- $0
- Hours/week
- 10
-
Kim SokoraiKIM SOKORAI
TRUSTEE
- Total calculated
- $0
- Hours/week
- 5
-
Vanessa DiasVANESSA DIAS
TRUSTEE
- Total calculated
- $0
- Hours/week
- 10
-
Jennifer RobertsonJENNIFER ROBERTSON
SECRETARY
- Total calculated
- $0
- Hours/week
- 10
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those.
Grants on this return
-
RAREBASE PBC
$86,000
BIOMARKER DISCOVERY PROJECT AND DRUG DISCOVERY PROJECT USING RAREBASE FUNCTION PLATFORM
-
STATE UNIVERSITY OF IOWA
$38,333
PHYSIOLOGICAL AND MOLECULAR SIGNATURES IN MOUSE MODELS OF MED13L SYNDROME
-
$25,787
STRATEGIC RESEARCH PLAN AND BIOSPECIMEN COLLECTION
-
PACIFIC IMMUNOLOGY
$7,143
PRODUCTION OF ANTIBODY FOR MED13L
Provenance
- Return type
- form_990
- Tax year
- 2023
- Filed
- 13 November 2024
- IRS schema version
- 2023v5.1
- Source object
- 202423199349309327
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.